Early increase of procalcitonin after cardiovascular surgery in patients with postoperative complications

Intensive Care Medicine

Volumn 28, Issue 8, 2002, Pages 1094-1102

  Meisner, M ^a   Rauschmayer, C ^b   Schmidt, J ^b   Feyrer, R ^b   Cesnjevar, R ^b   Bredle, D ^c   Tschaikowsky, K ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF WISCONSIN EAU CLAIRE   (United States)

Author keywords

C reactive protein; Calcitonin; Cardiopulmonary bypass; Infection; Inflammation; Sepsis; Thoracic surgery

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; INOTROPIC AGENT; PROCALCITONIN;

ARTERIAL OXYGEN TENSION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; RESPIRATORY FAILURE; ROC CURVE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

APACHE; C-REACTIVE PROTEIN; CALCITONIN; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASES; FEMALE; HEART VALVE PROSTHESIS; HUMANS; MALE; POSTOPERATIVE COMPLICATIONS; PROTEIN PRECURSORS; ROC CURVE; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0036373064     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-002-1392-5     Document Type: Article

References (54)

1. Procalcitonin
2. Outcome prediction by traditional and new markers of inflammation in patients with sepsis
3. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors and procalcitonin concentrations: Comparisons in patients with septic shock, cardiogenic shock and bacterial pneumonia
4. Procalcitonin used as a marker of infection in the intensive care unit
5. Postoperative plasma concentrations of procalcitonin after different types of surgery
6. Postoperative plasma concentration of procalcitonin and C-reactive protein in patients undergoing cardiac and thoracic surgery with and without cardiopulmonary bypass
7. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure and mortality in injured patients
8. Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome
9. Procalcitonin in early detection of postoperative complications
10. Hyperprocalcitoninemia in patients with noninfectious SIRS and pulmonary dysfunction associated with cardiopulmonary bypass
11. Effect of sepsis and cardiac surgery with cardiopulmonary bypass on plasma level of nitric oxide metabolites, neopterin and procalcitonin: Correlation with mortality and postoperative complications
12. APACHE II: A severity of disease classification system
13. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
14. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
15. Procalcitonin increase after endotoxin injection in normal subjects
16. Kinetics of procalcitonin in iatrogenic sepsis
17. Monokines, procalcitonin (ProCT) and opioid peptides course during a model of SIRS
18. Possible role of TNF on procalcitonin release in a baboon model of sepsis
19. In vitro and in vivo stimulation of procalcitonin by TNFα and IL-6
20. Evolution and significance of circulating procalcitonin levels compared with IL-6, TNFα and endotoxin levels early after thermal injury
21. Procalcitonin - A sepsis parameter in severe burn injuries
22. Effect of classic heat stroke on serum procalcitonin
23. Release of tumor necrosis factor, interleukin-2 and gamma-interferon in serum after injection of OKT2 monoclonal antibody in kidney transplant recipients
24. Procalcitonin in patients with sepsis and polytrauma
25. Procalcitonin release patterns in a baboon model of trauma and sepsis: Relationship to cytokines and neopterin
26. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis related cytokines in vitro
27. Is procalcitonin really a marker of sepsis?
28. Calcitonin gene expression in normal human liver
29. Procalcitonin and CGRP-1 mRNA expression in various human tissues
30. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro
31. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis
32. Clinical use and pathobiochemistry of procalcitonin
33. Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: The potential importance of bacterial translocation
34. Complement (C3, C4) and C-reactive protein responses to cardiopulmonary bypass and protamine administration
35. Interleukin-10 release related to cardiopulmonary bypass in infants undergoing cardiac operations
36. Preoperative and postoperative endotoxinemia in children with congenital heart disease
37. Elimination of procalcitonin and plasma concentrations during continuous veno-venous haemodiafiltration in septic patients
38. Plasma concentrations and clearance of procalcitonin during continuous veno-venous hemofiltration in septic patients
39. Procalcitonin: Erfahrungen mit einer neuen mess-groesse fuer bakterielle infektionen und systemische inflammation
40. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function
41. The natural elimination rate of procalcitonin in patients with normal and impaired renal function
42. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS
43. Procalcitonin as a marker of severity in septic shock
44. Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients
45. Hyperprocalcitonemia in patients with perioperative myocardial infarction after cardiac surgery
46. Inflammatory response to cardiopulmonary bypass: Mechanisms involved and possible therapeutic strategies
47. Systemic inflammatory responses to cardiopulmonary bypass: A pilot study of the effects of pentoxifylline
48. Pentoxifylline preloading reduces endothelial injury and permeability in cardiopulmonary bypass
49. Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients
50. Steroids in cardiopulmonary bypass
51. Corticosteroids during operations using cardiopulmonary bypass
52. Methylprednisolone does not benefit patients undergoing coronary artery bypass grafting and early tracheal extubation
53. Dexamethasone reduces the inflammatory response to cardiopulmonary bypass in children
54. Induction of procalcitonin and proinflammatory cytokines in an anhepatic baboon endotoxin shock model